TLR9 and colon carcinoma: Immunogenically dying CT26 colon carcinoma cells killed by MTO in vitro and adorned with CpG nanoparticles (adjuvant TLR9-agonist) have been already shown to foster maturation of DCs, T cell responses and antitumor responses in mouse models [50].